Hepatitis C Treatment and Residential Program Participation are the Two Compatible? A Case Study of Hepatitis C treatment at WHOS (We Help Ourselves).

ATCA Melbourne 2016

Presenter: Carolyn Stubley



WHOS TC Services

- Gunyah for men
- New Beginnings for women
- OSTAR (Opioid Substitution Treatment to Abstinence) mixed gender
- RTOD (Opioid Treatment Stabilisation) mixed gender
- WHOS Hunter Valley (mixed gender)
- WHOS Sunshine Coast (mixed gender)
- WHOS Newcastle Day Program OST





Harm Minimisation

- Commitment to the HM framework since mid 80's
- Ensuring health gains whilst in treatment
- Implementing Harm Reduction strategies
- Secondary NSP in all services because of BBV



WHOS Harm Reduction Initiatives

- Harm Reduction Workers provide education on overdose prevention/CPR, HIV & HEP C, Safe Sex and infection control
- Harm Reduction Nurse at Rozelle coordinates;
 - Sexual health, BBV screening and referral to treatment; Onsite Women's Health Clinic
- Onsite Liver Clinic/ Hep C treatment/Hep B



WHOS Liver Clinic

- In partnership with the Royal Prince Alfred Hospital Liver Clinic
- Providing Fibroscan onsite at WHOS Rozelle since2014
- Treatment prior to March 2016 not whilst in program
- Referral to the RPAH Liver Clinic post rehab



New Treatments

- PBS approval March 2016
- Clients wanting treatment
- Public Health message treat everyone
- Would it effect program participation?
- What part of the program?



Program participation

- TC Model peer group dynamics
- Structured daily programs- Group based
- Progression to employability skills Transition
- Outreach programs, working, training Exit



Reservations

The Old Treatments





Program Participation





Consultation & Education

- WHOS Managers consulted
- Education session for Managers RPAH Liver Clinic
- Education session for Harm Reduction Workers Hep C NSW
- WHOS Nursing staff training ASHM/RPAH Liver Clinic/Hep C NSW
- Clients consulted and Education provided from HEP C NSW



Outcomes of Consultation

- All managers in agreement
- Clients were keen to get treatment
- Decision to start with more senior clients post core program i.e. 90 days onwards
- Aim for approx 10 clients for induction per month
- Side effects to be monitored weekly



Treatment pathways

- Existing Liver Clinic onsite in partnership with RPAH –
 Fibroscan
- All screening and referral for treatment coordinated by Harm Reduction Nurse with WHOS visiting GP's
- Liver Clinic Doctors attending onsite to prescribe
- Liaison with community pharmacy would they supply the drugs – Cost+++



Characteristics of treatment

- One person requiring Ribavirin Genotype 2b, all others Genotype 1 & 3 new meds
- **▶** Fibroscan readings ranged from 3.5 − 20
- Most treatment duration 8-12 weeks; 1 @ 26 weeks
- Decision not to treat other genotypes 4 -6 with old medications – new treatments coming
- A mixture of abstinent and OST clients




Reported Side effects

- **▶** Sample size − First 18 clients on treatment
- Weekly monitoring
- Side effect free Not quite
- Manageable Yes
- Most side effects reported as slight the less you ask the less the side effects
- Several reported no side effects



Side effects





Managing side effects

- All but one client was managed with OTC symptomatic relief medication e.g. panadol
- Drink Water +++
- One client developed a fibromyalgia form of pain older client with cirrhosis
- Drug interaction website Hep Drug Interactions http://www.hep-druginteractions.org/checker



Progress

- Since March 2016 32 initiated on to treatment and 3 entering WHOS on treatment, Rozelle only
- Other WHOS TC's work with local liver clinics and now have clients on treatment
- Retention excellent whilst on treatment
- Treatment can commence earlier in program
- All clients so far have cleared



Conclusion

- Hepatitis C Treatment and program participation compatible YES
- Should clients be able to access Hep C treatment
 whilst in program Absolutely
- Public Health is blanketing treatment reduction/eradication



Acknowledgements

- **RPAH Liver Clinic**
- Nurses Magda Gawdry and Laura Murray
- Dr. Paul Haber
- WHOS Managers and Staff

